SENORES
Senores Pharmaceuticals Limited
Generics and CDMO/CMO services for regulated and emerging markets
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
senorespharma.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Senores Pharmaceuticals develops generic medicines for the US and other regulated markets, makes drugs for other companies on a contract development and manufacturing basis (CDMO/CMO), and sells in emerging markets, with plants in India and the US.
Company snapshot
55thBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
- ✓Net margin of 19.2% — the business keeps a healthy share of every rupee it earns.
- ✗Over the last three years operations used more cash than they brought in, despite an operating profit — the business is not yet turning its profit into cash.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 20261 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 103 Cr | 114 Cr | 138 Cr | 162 Cr | 175 Cr | 158 Cr | 180 Cr |
| Operating expenses (approx.) | 77 Cr | 95 Cr | 104 Cr | 112 Cr | 121 Cr | 128 Cr | 126 Cr |
| EBITDA | 26 Cr | 19 Cr | 34 Cr | 50 Cr | 54 Cr | 31 Cr | 54 Cr |
| OPM % | 24.9% | 17.0% | 24.8% | 30.6% | 30.9% | 19.4% | 29.8% |
| Other income | 5 Cr | 12 Cr | 3 Cr | 5 Cr | 4 Cr | 35 Cr | 3 Cr |
| Interest | 6 Cr | 5 Cr | 5 Cr | 6 Cr | 5 Cr | 8 Cr | 7 Cr |
| Depreciation | 4 Cr | 5 Cr | 6 Cr | 8 Cr | 8 Cr | 9 Cr | 10 Cr |
| Profit before tax | 20 Cr | 21 Cr | 26 Cr | 41 Cr | 45 Cr | 47 Cr | 39 Cr |
| Tax % | 19.8% | 13.1% | 20.0% | 25.9% | 24.7% | — | 22.8% |
| Net profit | 16 Cr | 18 Cr | 21 Cr | 30 Cr | 34 Cr | 37 Cr | 30 Cr |
| EPS (₹) | ₹5.04 | ₹3.81 | ₹4.60 | ₹6.54 | ₹7.29 | — | ₹6.61 |
- 1Mar 2026: Derived from year-to-date: the year to 31 Mar 2026 less the quarters to 30 Jun 2025, 30 Sep 2025 and 31 Dec 2025; the filing gives no figures for this quarter alone
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 14 Cr | 35 Cr | 215 Cr | 398 Cr | 633 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 12 Cr | 23 Cr | 173 Cr | 309 Cr | 464 Cr | Sign in free for the trailing twelve months |
| EBITDA | 2 Cr | 13 Cr | 42 Cr | 90 Cr | 168 Cr | Sign in free for the trailing twelve months |
| OPM % | 13.8% | 35.9% | 19.4% | 22.5% | 26.6% | Sign in free for the trailing twelve months |
| Other income | 0.46 Cr | 4 Cr | 3 Cr | 19 Cr | 47 Cr | Sign in free for the trailing twelve months |
| Interest | 0.56 Cr | 2 Cr | 9 Cr | 22 Cr | 25 Cr | Sign in free for the trailing twelve months |
| Depreciation | 0.70 Cr | 2 Cr | 10 Cr | 17 Cr | 31 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 1 Cr | 12 Cr | 25 Cr | 71 Cr | 159 Cr | Sign in free for the trailing twelve months |
| Tax % | 13.3% | 32.2% | -31.1% | 17.3% | 23.6% | Sign in free for the trailing twelve months |
| Net profit | 0.99 Cr | 8 Cr | 33 Cr | 58 Cr | 122 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | — | ₹8.87 | ₹13.67 | ₹16.12 | ₹26.39 | Sign in free for the trailing twelve months |
| Dividend payout % | — | — | — | 0.0% | 0.0% | Sign in free for the trailing twelve months |
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 9 Cr | 10 Cr | 31 Cr | 46 Cr | 46 Cr |
| Reserves | 28 Cr | 36 Cr | 174 Cr | 740 Cr | 888 Cr |
| Borrowings | 14 Cr | 61 Cr | 248 Cr | 305 Cr | 327 Cr |
| Other liabilities | 8 Cr | 25 Cr | 142 Cr | 110 Cr | 312 Cr |
| Total liabilities | 59 Cr | 131 Cr | 622 Cr | 1,227 Cr | 1,604 Cr |
| Fixed assets (net) | 5 Cr | 6 Cr | 152 Cr | 199 Cr | 331 Cr |
| CWIP | 0.35 Cr | 8 Cr | 18 Cr | 44 Cr | 17 Cr |
| Investments | 15 Cr | 16 Cr | 0.0070 Cr | 0.01 Cr | 29 Cr |
| Inventories | 3 Cr | 3 Cr | 37 Cr | 57 Cr | 89 Cr |
| Trade receivables | 20 Cr | 22 Cr | 112 Cr | 124 Cr | 325 Cr |
| Cash & bank | 2 Cr | 0.10 Cr | 8 Cr | 105 Cr | 46 Cr |
| Other assets | 13 Cr | 76 Cr | 295 Cr | 698 Cr | 766 Cr |
| Total assets | 59 Cr | 131 Cr | 622 Cr | 1,227 Cr | 1,604 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operating activity | -10 Cr | -1 Cr | -20 Cr | -46 Cr | 62 Cr |
| Cash from investing | -24 Cr | -48 Cr | -55 Cr | -429 Cr | -121 Cr |
| Cash from financing | 36 Cr | 46 Cr | 87 Cr | 573 Cr | -1 Cr |
| Net cash flow | 2 Cr | -3 Cr | 12 Cr | 98 Cr | -60 Cr |
| Free cash flow (OCF − Capex) | -21 Cr | -48 Cr | -72 Cr | -203 Cr | -178 Cr |
Ratios
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | 3.4% | 13.7% | 7.2% | 8.2% | 14.3% |
| ROE % | 2.7% | 18.5% | 13.6% | 7.2% | 12.6% |
| Debtor days | 504 | 228 | 191 | 113 | 187 |
| Inventory days | 1085812 | 3296 | 427 | 225 | 284 |
| Days payable | 2597504 | 14330 | 1291 | 267 | 748 |
| Cash conversion cycle | -1511188 | -10806 | -673 | 71 | -276 |
| OCF / EBITDA % | -535.2% | -8.5% | -47.8% | -51.2% | 36.9% |
| OCF / EBITDA % (3 years) | — | — | -55.9% | -46.5% | -1.2% |
| Debt / equity | 0.39 | 1.34 | 1.22 | 0.39 | 0.35 |
| Current ratio | 2.74 | 0.99 | 1.01 | 3.00 | 1.92 |
| Net debt / EBITDA | 6.24 | 4.79 | 5.79 | 2.22 | 1.67 |